- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:02 | OS Therapies: OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma | 227 | Newsfile |
ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for small and medium-sized enterprises (SMEs)... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 09.03. | OS Therapies: OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting | 295 | Newsfile | FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New... ► Artikel lesen | |
| 06.03. | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings | 1 | Benzinga.com | ||
| 17.02. | OS Therapies: OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma | 411 | Newsfile | Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S., U.K. and European osteosarcoma key... ► Artikel lesen | |
| 13.02. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | OS Therapies: OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies | 422 | Newsfile | New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is... ► Artikel lesen | |
| 02.02. | OS Therapies: OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 421 | Newsfile | Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's request, Type D Meeting expected in March 2026 to review Comparative... ► Artikel lesen | |
| 15.01. | OS Therapies Bone Cancer Trial Data Strengthens FDA Case | 3 | Benzinga.com | ||
| 15.01. | OS Therapies: OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 177 | Newsfile | Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (Pre-specified pathway analysis strategy developed as... ► Artikel lesen | |
| 14.01. | OS Therapies: OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | 457 | Newsfile | OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first... ► Artikel lesen | |
| 12.01. | OS Therapies: OS Therapies Enters into Warrant Inducement Agreements | 240 | Newsfile | $7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet proceeds to fund OST-HER2 regulatory approval... ► Artikel lesen | |
| 12.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | OS Therapies provides first half 2026 corporate outlook | 3 | Seeking Alpha | ||
| 05.01. | OS Therapies: OS Therapies Provides First Half 2026 Corporate Outlook | 466 | Newsfile | Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary... ► Artikel lesen | |
| 09.12.25 | OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 402 | Newsfile | Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint... ► Artikel lesen | |
| 05.12.25 | OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility | 539 | Newsfile | U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency... ► Artikel lesen | |
| 25.11.25 | OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization | 406 | Newsfile | New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today... ► Artikel lesen | |
| 20.11.25 | OS Therapies to spin off OS Animal Health into a standalone public company | 5 | Seeking Alpha | ||
| 20.11.25 | OS Therapies plans to spin off animal health unit as public company | 5 | Investing.com |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 40,800 | +1,49 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| IMMUNIC | 1,098 | +1,86 % | Immunic garners new Buy at Guggenheim on lead asset | ||
| PHIO PHARMACEUTICALS | 1,220 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement | King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,551 | -29,65 % | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease | NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,655 | 0,00 % | Arcturus Therapeutics: Strategische Neuausrichtung auf seltene Krankheiten | ||
| ZEVRA THERAPEUTICS | 8,150 | +3,82 % | Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) | ||
| PROTALIX BIOTHERAPEUTICS | 1,750 | -2,23 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®... ► Artikel lesen | |
| GEOVAX LABS | 1,510 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax Provides Update on GEO-MVA Program | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Provides Update on GEO-MVA Program 25.03.2026 / 14:03 CET/CEST
The issuer is solely responsible for the content of this... ► Artikel lesen | |
| SCILEX | 5,630 | -1,75 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.02.2026 | The following instruments on XETRA do have their first trading 10.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.02.2026
Aktien
1 CNE100006V73 Auntea Jenny (Shanghai)... ► Artikel lesen | |
| INVIVYD | 1,435 | 0,00 % | Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates | Achieved Q4 2025 PEMGARDA (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7... ► Artikel lesen | |
| MEIRAGTX | 6,550 | +2,34 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,743 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 6,390 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission |
DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen |
OS THERAPIES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,400 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.